Skip to main content

Logistics and Waste Management Benefits of depo-subQ in Uniject

This four-page brief describes results from three analyses conducted by PATH and John Snow Inc. (JSI) comparing the intramuscular version of depot medroxyprogesterone acetate (DMPA) injectable contraceptive compared with the new DMPA-SC formulation packaged in the Uniject injection system. The analyses focused on waste management implications and identified key quantitative and qualitative differences between the two products.

Institutional Author(s): PATH, JSI
Publication date: February, 2011